Drugs / Peldesine
Peldesine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00002237 | — | HIV infectious disease | BioCryst Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-10-09 | BioCryst Pharmaceuticals | Results BIOCRYST PHARMACEUTICALS, INC. ANNOUNCES PRELIMINARY PHASE II TRIAL DATA FOR A TOPICAL OINTMENT FORMULATION OF PNP DRUG CANDIDATE, BCX-34 biocryst.com ↗
Initial results from the double-blind trial demonstrated no statistical differences in study endpoints between BCX-34-treated and placebo-treated lesions. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-10-09 | BioCryst Pharmaceuticals | BIOCRYST PHARMACEUTICALS, INC. ANNOUNCES PRELIMINARY PHASE II TRIAL DATA FOR A TOPICAL OINTMENT FORMULATION OF PNP DRUG CANDIDATE, BCX-34 biocryst.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peldesine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002237 ↗ |
| Known as | BCX-34 | “Phase I Placebo-Controlled Study of Oral BCX-34 (Peldesine) in HIV-Infected Patients” NCT00002237 ↗ |
| Known as | Peldesina | ChEMBL registry synonym — accepted as the source's own label CHEMBL311300 ↗ |
| Modality | Small molecule | — CHEMBL311300 ↗ |
| Route | Oral | “Phase I Placebo-Controlled Study of Oral BCX-34 (Peldesine) in HIV-Infected Patients” NCT00002237 ↗ |